A four-week yoga program significantly reduced insomnia, fatigue, anxiety, and mood disturbances in cancer survivors, according to a study presented at the 2026 American Society of Clinical Oncology (ASCO) meeting. The trial, led by the University of Rochester Medical Center, involved 410 participants and demonstrated that “moderate-to-large” improvements in mood disturbance and “medium-to-large” reductions in fatigue correlated with better sleep quality, according to researchers.
The YOCAS Trial: A Multisite Breakthrough
The Yoga for Cancer Survivors (YOCAS) program, which combined 18 gentle Hatha and restorative yoga poses, breathing exercises, and mindfulness techniques, showed “meaningfully less” overall mood disturbance compared to standard care, with effects described as “moderate-to-large” by the University of Rochester Medical Center. The study, conducted across multiple U.S. community cancer care sites, included 204 participants in the control group and 206 in the yoga group, with no prior regular yoga practice among participants. “This indicates that cancer survivors have an option to alleviate these cancer-related side effects at the same time, without adding another drug,” said lead investigator Yuri Choi, RN, PhD, of the Wilmot Cancer Institute.
Participants attended two 75-minute instructor-led yoga sessions weekly, with additional home-based practice. The program’s focus on slow, gentle movements and mindfulness distinguished it from more intense yoga styles, which researchers emphasized were not part of the trial. “Just doing downward dog without the breathing and mindfulness is simply calisthenics,” noted Karen Mustian, PhD, senior author and dean’s professor of Surgery at Wilmot Cancer Institute.
Why Gentle Yoga Matters
The study highlighted the importance of tailored interventions for cancer survivors, many of whom struggle with persistent symptoms like fatigue and anxiety. “There is no single gold standard behavioural treatment available to survivors for treating overall mood disturbance, anxiety, fatigue, and insomnia,” Choi stated. The trial’s results align with broader efforts to address the “significant morbidity” linked to these side effects, which can interfere with daily life and quality of life.
While the YOCAS program showed strong efficacy, other studies presented at the same ASCO meeting explored alternative treatments. A separate trial found that the antidepressant bupropion improved fatigue in cancer survivors, particularly among women and former smokers, though subgroup analyses revealed no benefit for men. Another study found that exercise combined with the stimulant methylphenidate had limited impact on fatigue, with all groups showing placebo-like improvements.
Implications and Future Directions
The YOCAS findings suggest that non-pharmacological approaches could complement existing treatments, offering a “four bangs for your buck” solution for multiple symptoms. “People tend to enjoy it, and our research shows that after one month of restorative yoga, a person may see major improvements,” Mustian said. However, the study’s preliminary nature and lack of peer review underscore the need for further validation.
Researchers stress that the program’s safety profile was favorable, with only one adverse event reported, unrelated to the yoga practice. The study’s focus on gentle Hatha and restorative yoga also addresses barriers to exercise for survivors with physical limitations, providing a “safer and more comfortable option” compared to high-intensity workouts.
The results add to a growing body of evidence supporting integrative care for cancer survivors. As the National Cancer Institute funded the trial, the findings could influence clinical guidelines, encouraging clinicians to recommend yoga as a complementary therapy. However, challenges remain in scaling such programs, particularly in underserved areas where access to trained instructors may be limited.
For now, the YOCAS trial offers a compelling case for yoga as a low-risk, accessible intervention. As Choi noted, “Part of the reason YOCAS may improve insomnia may be because it reduces mood disturbance and fatigue.” With cancer survival rates rising, the demand for effective, holistic solutions is unlikely to wane.
Source 1 Source 2 Source 3 Source The YOCAS trial's findings have the potential to inform and shape the way clinicians approach complementary therapies for insomnia, potentially benefiting millions of people worldwide.
